文献速递妇产影像泌尿生殖MR

基于MRI影像-临床列线图判定p53abn子宫内膜癌的多任务分析

Determination of p53abn endometrial cancer: a multitask analysis using radiological-clinical nomogram on MRI.
PubMed 文献 · Br J Radiol · 2024-01-01

该回顾性研究纳入227例病理证实的子宫内膜癌患者,基于MRI提取影像组学特征联合临床特征构建列线图,用于区分非子宫内膜样癌、高危组及p53abn亚型。联合模型鉴别p53abn的测试AUC为0.845,优于临床模型(AUC 0.834 vs 0.682)。

要点

  • 增强T1WI是区分p53abn与非p53abn的最佳MRI序列(测试AUC 0.8)。
  • 联合各序列最佳特征的模型鉴别p53abn的测试AUC达0.845。
  • 影像组学模型鉴别p53abn优于临床模型(AUC 0.834 vs 0.682)。

核心结论

  • 联合影像组学与临床特征的诊断模型在区分非子宫内膜样癌及p53abn与其他分子亚组方面表现更优,可能有助于设计针对性治疗,尤其对高危子宫内膜癌患者。

研究设计与样本

  • 回顾性研究,纳入本机构227例病理证实的子宫内膜癌患者,均接受基于癌症基因组图谱的分子病理诊断,从在线Pyradiomics处理器提取影像组学特征。

关键影像表现/征象

  • 增强T1WI是区分p53abn与非p53abn的最佳MRI序列(测试AUC 0.8)。
  • 表观扩散系数图是区分子宫内膜样癌与非子宫内膜样癌(测试AUC 0.665)以及高危与低-中危组(测试AUC 0.690)的最佳MRI序列。

诊断标准与关键数值

  • 联合模型鉴别p53abn的测试AUC为0.845。
  • 影像组学模型鉴别p53abn的AUC为0.834,临床模型为0.682。
  • 增强T1WI鉴别p53abn与非p53abn的测试AUC为0.8。
  • 表观扩散系数图区分子宫内膜样癌与非子宫内膜样癌的测试AUC为0.665,区分高危与低-中危组的测试AUC为0.690。

临床应用与阅片要点

  • 增强T1WI可用于区分p53abn与非p53abn子宫内膜癌(测试AUC 0.8)。
  • 表观扩散系数图可用于区分子宫内膜样癌与非子宫内膜样癌及高危与低-中危组。
  • 联合各序列最佳特征的模型在三个任务中均表现最佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to differentiate endometrial cancer (EC) between TP53mutation (P53abn) and Non-P53abn subtypes using radiological-clinical nomogram on EC body volume MRI.

METHODS: We retrospectively recruited 227 patients with pathologically proven EC from our institution. All these patients have undergone molecular pathology diagnosis based on the Cancer Genome Atlas. Clinical characteristics and histological diagnosis were recorded from the hospital information system. Radiomics features were extracted from online Pyradiomics processors. The diagnostic performance across different acquisition protocols was calculated and compared. The radiological-clinical nomogram was established to determine the nonendometrioid, high-risk, and P53abn EC group.

RESULTS: The best MRI sequence for differentiation P53abn from the non-P53abn group was contrast-enhanced T1WI (test AUC: 0.8). The best MRI sequence both for differentiation endometrioid cancer from nonendometrioid cancer and high-risk from low- and intermediate-risk groups was apparent diffusion coefficient map (test AUC: 0.665 and 0.690). For all 3 tasks, the combined model incorporating all the best discriminative features from each sequence yielded the best performance. The combined model achieved an AUC of 0.845 in the testing cohorts for P53abn cancer identification. The MR-based radiomics diagnostic model performed better than the clinical-based model in determining P53abn EC (AUC: 0.834 vs 0.682).

CONCLUSION: In the present study, the diagnostic model based on the combination of both radiomics and clinical features yielded a higher performance in differentiating nonendometrioid and P53abn cancer from other EC molecular subgroups, which might help design a tailed treatment, especially for patients with high-risk EC.

ADVANCES IN KNOWLEDGE: (1) The contrast-enhanced T1WI was the best MRI sequence for differentiation P53abn from the non-P53abn group (test AUC: 0.8). (2) The radiomics-based diagnostic model performed better than the clinical-based model in determining P53abn EC (AUC: 0.834 vs 0.682). (3) The proposed model derived from multi-parametric MRI images achieved a higher accuracy in P53abn EC identification (AUC: 0.845).

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Ning Y, Liu W, Wang H, et al. Determination of p53abn endometrial cancer: a multitask analysis using radiological-clinical nomogram on MRI. Br J Radiol. 2024. PMID: 38538868. doi:10.1093/bjr/tqae066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。